Antibody for specifically binding to lysyl-tRNA synthetase N-terminal domain exposed to extracellular membrane
AssigneeZymedi Co., Ltd.
InventorsSunghoon Kim, Nam Hoon Kwon
Life of this patent
Estimating the term…
Loading patent…
AssigneeZymedi Co., Ltd.
InventorsSunghoon Kim, Nam Hoon Kwon
Estimating the term…
The present invention relates to an antibody that specifically binds to the lysyl-tRNA synthase N-terminal domain exposed to the extracellular membrane, more specifically, it specifically binds to the lysyl-tRNA synthetase (KRS, Lysyl-tRNA synthetase)N-terminal domain exposed to the extracellular membrane having a specific CDR (complementarity determining region) sequence described herein, and relates to the use for the prevention, treatment or diagnosis of cancer, cancer metastasis, or diseases related to immune cell migration of a composition comprising an antibody or fragment thereof having high affinity and stability or the antibody and fragment thereof as an active ingredient. The method of the present invention can be usefully used to prepare an antibody having a higher affinity for the KRS N-terminus than a conventional antibody.
An antibody or fragment thereof that specifically binds to an extracellularly exposed lysyl-tRNA synthetase (KRS)N-terminal region, the antibody or fragment thereof comprises:
Dependencies are inferred from the claim text.